Credit Suisse Upgrades Myriad Genetics, Downgrades Genomic Health | GenomeWeb

NEW YORK (GenomeWeb News) – Credit Suisse today upgraded Myriad Genetics' stock and raised the price target on its shares, while it downgraded Genomic Health and lowered the price target on that firm's shares.

In a research note, analyst Vamil Divan upgraded Myriad to a Neutral rating from a previous Underperform rating and increased its share price target to $29 from $18. He downgraded Genomic Health to Neutral from Outperform and reduced the price target on its shares to $28 from $36.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: CRISPR-based barcodes to trace cell lineages, and more.

The director of the National Institutes of Health Francis Collins sang the national anthem this week before a baseball game.

French researchers criticize unexpected government plan to cut research funding, ScienceInsider reports.

In Nature this week: genetic mechanism through which some cancers evade the immune system, and more.